{
  "id": "2247620354_1",
  "title": "「药捷安康」明日登录港交所，暗盘交易上涨 69.2%",
  "content": "<div class=\"rich_media_content js_underline_content autoTypeSetting24psection\" id=\"js_content\">\n <section data-mpa-powered-by=\"yiban.io\" style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(34, 34, 34);background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.75em;'>\n  <a class=\"weapp_image_link js_weapp_entry\" data-miniprogram-appid=\"wx33d4c3735820a33e\" data-miniprogram-applink=\"\" data-miniprogram-imageurl=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgkTd5kOMyjSvsR1rfXuXEg3IO5DRKXOicj8tyI239IlQVqrhNBxQia1RQ/640?wx_fmt=png&amp;from=appmsg\" data-miniprogram-nickname=\"Insight医药情报助手\" data-miniprogram-path=\"pages/upgrade/premium/index\" data-miniprogram-servicetype=\"0\" data-miniprogram-type=\"image\" style=\"font-size:15px;\">\n   <img class=\"rich_pages wxw-img\" data-croporisrc=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgkTd5kOMyjSvsR1rfXuXEg3IO5DRKXOicj8tyI239IlQVqrhNBxQia1RQ/0?wx_fmt=png&amp;from=appmsg\" data-cropselx2=\"562\" data-cropsely2=\"148\" data-imgfileid=\"100133279\" data-ratio=\"0.26382978723404255\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgkTd5kOMyjSvsR1rfXuXEg3IO5DRKXOicj8tyI239IlQVqrhNBxQia1RQ/640?wx_fmt=png&amp;from=appmsg\" style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;text-align: center;color: rgba(0, 0, 0, 0.9);visibility: visible !important;width: 1080px !important;height: auto !important;\"/>\n  </a>\n </section>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span data-mpa-action-id=\"mc1p8spi8wi\" leaf=\"\" style=\"font-size: 15px;\">\n   6 月 23 日上午 9 点，药捷安康将在港交所正式上市。本次 IPO 引入多名基石投资者，包括\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    江北医药、康方生物、华盛敦行、药石地平线、科瓴安\n   </span>\n   ，共计认购 1.3 亿港元\n  </span>\n  <span data-mpa-action-id=\"mc1p8spi8wi\" leaf=\"\" style=\"line-height: 1.75em;font-size: 15px;\">\n   。\n  </span>\n  <span data-mpa-action-id=\"mc6xn1a43pa\" data-pm-slice=\"0 0 []\" leaf=\"\" mpa-font-style=\"mc6xn19stmo\" style=\"font-size: 15px;\">\n   富途牛牛行情显示，\n  </span>\n  <span leaf=\"\" style=\"line-height: 1.75em;font-size: 15px;\">\n   截至 6 月 20 日收盘，药捷安康暗盘交易报价显示为 22.25 港元/股，比招股价 13.15 港元\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    上涨 69.2%\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   药捷安康成立于 2014 年，专注于研发\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    肿瘤、炎症\n   </span>\n   及\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    心脏代谢疾病\n   </span>\n   小分子创新疗法。该公司创始人、董事长兼 CEO 为\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    吴永谦\n   </span>\n   博士，他在生物制药领域拥有超过 27 年的科学以及领导经验。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在本次 IPO 之前，药捷安康已完成多轮融资，投资人包括基科发展、先进制造基金、CPE Investment、结构调整基金等多家机构。药捷安康的 IPO 之路非常波折，该公司在 2021-2025 年之间\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   曾\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   先后四次向港交所递表，直到今年 6 月才成功登录港陆。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"293\" data-backw=\"578\" data-imgfileid=\"100136543\" data-ratio=\"0.5065913370998116\" data-s=\"300,640\" data-type=\"png\" data-w=\"1062\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8sfrH2Fh8k0NTibfMoWpicnGlGLicVMJtFWBEdY0xQLqYtRAanBIX0LVb08TXyI5c7tJyHWFLyvm1oHQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;height: auto !important;\" type=\"block\"/>\n </section>\n <section style=\"text-align: center;\">\n  <span data-mpa-action-id=\"mc1pdj151nex\" data-pm-slice=\"0 0 []\" style='color: rgb(178, 178, 178);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;'>\n   <span mpa-font-style=\"mc1pdj0h1yrv\" style=\"font-size: 12px;\">\n    <span data-mpa-action-id=\"mc1pdj0h1mtb\" leaf=\"\">\n     截图来源：\n    </span>\n    <span data-mpa-action-id=\"mc1pdj0hvoq\" data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n     药捷安康招股书\n    </span>\n   </span>\n  </span>\n </section>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   根据招股书，药捷安康开发了 7 款产品管线，包括 3 款肿瘤领域候选药物和 4 款非肿瘤候选药。其中，有 6 款产品在临床阶段，1 款在临床前阶段。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n         <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;letter-spacing: 0.544px;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;visibility: visible;'>\n          <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n          </span>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    肿瘤管线\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   药捷安康的核心产品\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    Tinengotinib\n   </span>\n   <span style=\"color: rgb(0, 0, 0);font-weight: bold;\" textstyle=\"\">\n    (TT00420)\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    是一种多靶点激酶\n   </span>\n   <span style=\"color: rgb(136, 136, 136);font-weight: normal;\" textstyle=\"\">\n    （MTK）\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    抑制剂\n   </span>\n   ，主要靶向三个关键通路——即 FGFR/VEGFR、JAK 和 Aurora 激酶。该药正在进行两项关键性/注册临床试验，用于治疗在过往接受 FGFR 抑制剂治疗后疾病发生进展的\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    胆管癌\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   同时，药捷安康还在探索将 Tinengotinib 用于治疗转移性去势抵抗性前列腺癌\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （mCRPC）\n   </span>\n   、乳腺癌、胆道系统癌症\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （BTC）\n   </span>\n   及泛 FGFR 实体瘤的效果，并已完成 II 期临床研究；并将在 II 期试验中评估 Tinengotinib 联合卡度尼利单抗或依沃西单抗治疗肝细胞癌\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （HCC）\n   </span>\n   的效果。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   Tinengotinib 已在\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    胆管癌\n   </span>\n   的早期研究中取得积极结果。在美国开展的一项临床研究汇总分析显示，截至 2024 年 3 月 28 日，43 名先前已使用 FGFR 抑制剂治疗但发生疾病进展的\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"font-weight: normal;\" textstyle=\"\">\n    胆管癌\n   </span>\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   患者接受了 Tinengotinib 治疗，并进行了至少一次肿瘤扫描，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    客观缓解率（ORR）为 30%\n   </span>\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    (13/43)\n   </span>\n   ，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    疾病控制率（DCR）为 93%\n   </span>\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    (40/43)\n   </span>\n   ，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    中位无进展生存期（PFS）为 6.0 个月\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在中国进行的临床试验数据显示：三名先前已使用 FGFR 抑制剂治疗但发生疾病进展的\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"font-weight: normal;\" textstyle=\"\">\n    胆管癌\n   </span>\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   患者接受 Tinengotinib 治疗，其中两名患者\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    (66.7%)\n   </span>\n   达致部分缓解。截至 2024 年 3 月 28 日，一名患者持续超过治疗 8 个月，而另一名患者已持续治疗 14 个月且仍在接受治疗。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在美国及中国患者的汇总分析中，Tinengotinib\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    单药用于既往接受过多线治疗的 mCRPC 患者\n   </span>\n   也显出初步的抗疗效。I 期/II 期临床试验中，Tinengotinib 对有可评价疗效的 22 名 mCRPC 患者进行单药治疗的数据显示\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    ： ORR 为 46%\n   </span>\n   <span style=\"color: rgb(136, 136, 136);font-weight: normal;\" textstyle=\"\">\n    (6/13)\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    、DCR 为 85%\n   </span>\n   <span style=\"color: rgb(136, 136, 136);font-weight: normal;\" textstyle=\"\">\n    (11/13)\n   </span>\n   ；43% 的患者前列腺特异性抗原减少超过 50%；中位影像学 PFS 为 5.6 个月\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    (N=22)\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;margin-bottom: 24px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在联合疗法方面，Tinengotinib 已获得 FDA 批准，可进行与白蛋白结合型紫杉醇联合治疗乳腺癌的 I/II 期试验，并在美国完成了 Ib 期试验。在中国，NMPA 已批准 Tinengotinib 与 PD-L1 联合治疗 BTC 的 I/II 期试验，以及 Tinengotinib 与 NHT 联合治疗 mCRPC 的 II 期试验。\n  </span>\n </p>\n <p data-mpa-action-id=\"mc1pvwcdkd0\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mc1pvwbpyes\" style=\"line-height: 1em;margin-top: 24px;text-align: center;margin-bottom: 0px;font-size: 14px;\">\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n   药捷安康抗肿瘤管线\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin: 8px 8px 0px;line-height: 1em;\">\n  <img class=\"rich_pages wxw-img\" data-backh=\"208\" data-backw=\"578\" data-imgfileid=\"100136544\" data-ratio=\"0.36018518518518516\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8sfrH2Fh8k0NTibfMoWpicnGlfiaIPymsy4tbXvsumNcTzicp2B5lCliazuJ9TXwBmuqJG7pSpibrOW7A5g/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;height: auto !important;\" type=\"block\"/>\n </section>\n <section style=\"text-align: center;\">\n  <span data-mpa-action-id=\"mc1pdj151nex\" data-pm-slice=\"0 0 []\" style='color: rgb(178, 178, 178);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;'>\n   <span data-pm-slice='2 2 [\"para\",{\"tagName\":\"section\",\"attributes\":{\"style\":\"text-align: center;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"node\",{\"tagName\":\"span\",\"attributes\":{\"style\":\"color: rgb(178, 178, 178);font-family: \\\"PingFang SC\\\", system-ui, -apple-system, BlinkMacSystemFont, \\\"Helvetica Neue\\\", \\\"Hiragino Sans GB\\\", \\\"Microsoft YaHei UI\\\", \\\"Microsoft YaHei\\\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;\",\"data-pm-slice\":\"0 0 []\",\"data-mpa-action-id\":\"mc1pdj151nex\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' mpa-font-style=\"mc1pdj0h1yrv\" style=\"font-size: 12px;\">\n    <span data-mpa-action-id=\"mc1pdj0h1mtb\" leaf=\"\">\n     截图来源：\n    </span>\n    <span data-mpa-action-id=\"mc1pdj0hvoq\" data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n     药捷安康招股书\n    </span>\n   </span>\n  </span>\n </section>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   药捷安康的肿瘤管线还有两款产品：\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    TT-00973 是一种高效 AXL/FLT3 抑制剂\n   </span>\n   ，正在中国开展治疗实体瘤的 I 期研究；\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    TT-01488 是一种非共价可逆 BTK 抑制剂\n   </span>\n   ，旨在克服多种复发性或难治性血液恶性肿瘤中由已上市共价 BTK 抑制剂产生的获得性耐药。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;margin-bottom: 0px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   TT-01488 目前正在中国进行 TT-01488 治疗 B 细胞淋巴瘤的 I 期临床研究。截至 2024 年 10 月 2 日，这项 I 期研究共入组 18 名既往接受过 B 细胞恶性肿瘤治疗的患者。研究数据显示：\n  </span>\n </p>\n <ul class=\"list-paddingleft-1\" style=\"list-style-type: circle;\">\n  <li>\n   <p style=\"line-height: 1.75em;margin-top: 8px;\">\n    <span leaf=\"\" style=\"font-size: 15px;\">\n     TT-01488 在所有患者中均具有良好的耐受性。\n    </span>\n   </p>\n  </li>\n  <li>\n   <p style=\"line-height: 1.75em;margin-top: 8px;\">\n    <span leaf=\"\" style=\"font-size: 15px;\">\n     在 14 名可评估疗效的患者中，ORR 为 57%，包括 3 名完全缓解\n     <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n      （CR）\n     </span>\n     、5 名部分缓解\n     <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n      （PR）\n     </span>\n     。\n    </span>\n    <span style=\"font-size: 15px;letter-spacing: 0.034em;background-color: transparent;\">\n     <span leaf=\"\">\n      在患有套细胞淋巴瘤\n      <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n       （MCL）\n      </span>\n      、华氏巨球蛋白血症\n      <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n       （WM）\n      </span>\n      及 边缘区淋巴瘤\n      <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n       （MZL）\n      </span>\n      的患者中，\n      <span style=\"font-weight: bold;\" textstyle=\"\">\n       观察到的 ORR 为 100%\n      </span>\n      <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n       (7/7)\n      </span>\n      。\n     </span>\n    </span>\n   </p>\n  </li>\n </ul>\n <p style=\"line-height: 1.75em;margin-top: 24px;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n         <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;letter-spacing: 0.544px;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;visibility: visible;'>\n          <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n          </span>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    非肿瘤管线\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   药捷安康的非肿瘤领域有 4 款产品，其中三款已进入临床阶段，分别如下。\n  </span>\n </p>\n <p data-mpa-action-id=\"mc1pvo7hp2o\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mc1pvo6s1zx5\" style=\"line-height: 1em;margin-top: 8px;text-align: center;margin-bottom: 0px;font-size: 14px;\">\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1em; margin-top: 8px; text-align: center; margin-bottom: 0px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n   药捷安康非肿瘤领域管线\n  </span>\n </p>\n <p style=\"line-height: 1em;margin-top: 8px;text-align: center;margin-bottom: 0px;\">\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1em; margin-top: 8px; text-align: center; margin-bottom: 0px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   <br/>\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 0px;\">\n  <img class=\"rich_pages wxw-img\" data-backh=\"34\" data-backw=\"578\" data-imgfileid=\"100136547\" data-ratio=\"0.058333333333333334\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8sfrH2Fh8k0NTibfMoWpicnGl9iamWug9icryIXIjQR7AoKmn7lzicicHxOq6ozb1cTPITtGzvxb0gXibATw/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;height: auto !important;\" type=\"block\"/>\n </section>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-backh=\"67\" data-backw=\"562\" data-imgfileid=\"100136546\" data-ratio=\"0.11944444444444445\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8sfrH2Fh8k0NTibfMoWpicnGlZrfv8ZWdEkibcRfFHHalnTqhIpw3daZv1DACPMRdMQF8QdJ5r4jNrCA/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;height: auto !important;\" type=\"block\"/>\n </section>\n <section style=\"text-align: center;\">\n  <span data-mpa-action-id=\"mc1pdj151nex\" data-pm-slice=\"0 0 []\" style='color: rgb(178, 178, 178);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;'>\n   <span data-pm-slice='2 2 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"para\",{\"tagName\":\"section\",\"attributes\":{\"style\":\"text-align: center;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"node\",{\"tagName\":\"span\",\"attributes\":{\"style\":\"color: rgb(178, 178, 178);font-family: \\\"PingFang SC\\\", system-ui, -apple-system, BlinkMacSystemFont, \\\"Helvetica Neue\\\", \\\"Hiragino Sans GB\\\", \\\"Microsoft YaHei UI\\\", \\\"Microsoft YaHei\\\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;\",\"data-pm-slice\":\"0 0 []\",\"data-mpa-action-id\":\"mc1pdj151nex\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' mpa-font-style=\"mc1pdj0h1yrv\" style=\"font-size: 12px;\">\n    <span data-mpa-action-id=\"mc1pdj0h1mtb\" leaf=\"\">\n     截图来源：\n    </span>\n    <span data-mpa-action-id=\"mc1pdj0hvoq\" data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n     药捷安康招股书\n    </span>\n   </span>\n  </span>\n </section>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   TT-01688 是药捷安康从 LG Chem 引进的\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    一种高选择性口服 S1P1 调节剂\n   </span>\n   ，目前处于临床阶段，具有\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    治疗各种炎症性疾病\n   </span>\n   的潜力。Insight 数据库显示，中国目前有三款 S1P1 调节剂获批，但适应症都是多发性硬化，尚无选择性 S1P1 调节剂获批准用于溃疡性结肠炎\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （UC）\n   </span>\n   或特应性皮炎\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （AD）\n   </span>\n   治疗。TT-01688 已在中国完成治疗 UC 的 Ib 期临床试验，以及治疗 AD 的 II 期临床试验。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   TT-00920 是药捷安康自主研发的\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    一种高选择性口服 PDE9 抑制剂\n   </span>\n   <span style=\"font-weight: normal;\" textstyle=\"\">\n    ，\n   </span>\n   拟开发治疗\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    慢性心力衰竭\n   </span>\n   ，该药的海外权益已授权给 LG Chem 公司。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   TT-01025 是\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    一种不可逆 VAP-1 抑制剂，拟用于 NASH 的治疗\n   </span>\n   ，目前在Ⅰ期临床阶段。VAP-1 是新型的临床抗炎靶点。Insight 数据库显示，全球尚无 VAP-1 抑制剂获批，目前有 6 种 VAP-1 抑制剂处于临床阶段\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （仅统计活跃状态）\n   </span>\n   。TT-01025 是中国首款且目前唯一正在开展临床试验的 VAP-1 抑制剂。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   根据招股书，截至 2024 年 12 月 31 日，药捷安康的年末现金及现金等价物为 5.695 亿元。本次募集资金用途为：\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   (i) 约 90.0% 将用于核心产品 Tinengotinib 正在进行的单药治疗\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"font-weight: normal;\" textstyle=\"\">\n    胆管癌\n   </span>\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   的国际多中心注册 III 期临床试验。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-top: 8px;\">\n  <span data-mpa-action-id=\"mc1p8spi3ev\" leaf=\"\" style=\"font-size: 15px;\">\n   (ii) 约 10.0% 将分配用于公司的一般营运资金以及一般公司用途。\n  </span>\n </p>\n <p style=\"line-height: 1em;margin-top: 8px;margin-bottom: 8px;\">\n  <span data-mpa-action-id=\"mc6xt1j6uov\" leaf=\"\" style=\"font-size: 12px;\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    参考资料：\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1em;margin-top: 8px;margin-bottom: 8px;\">\n  <span data-mpa-action-id=\"mc1p8spi3ev\" leaf=\"\" style=\"font-size: 12px;\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    [1]\n   </span>\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-top: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 12px;\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    药捷安康招股书\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1em;margin-top: 8px;margin-bottom: 8px;\">\n  <span data-mpa-action-id=\"mc6xt1j61mks\" leaf=\"\" style=\"font-size: 12px;\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    [2]富途牛牛。\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin: 24px 8px 0px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 15px;visibility: visible;\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;text-align: left;color: rgb(178, 178, 178);font-size: 12px;\">\n    <span leaf=\"\">\n     免责声明：\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;text-align: left;color: rgb(178, 178, 178);font-size: 12px;\">\n    <span leaf=\"\">\n     本文仅作消息分享，\n    </span>\n   </span>\n   <span style='-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;text-align: left;font-size: 12px;color: rgb(165, 165, 165);font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;'>\n    <span leaf=\"\">\n     并不构成投资建议，也不代表 Insight 数据库的立场，文章观点仅供分享行业见解，请广大投资者谨慎。\n    </span>\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: left;visibility: visible;line-height: 1.75em;'>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: left;visibility: visible;line-height: 1.75em;'>\n  <strong style='-webkit-tap-highlight-color: transparent;outline: 0px;color: rgb(178, 178, 178);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);visibility: visible;'>\n   <span leaf=\"\">\n    编辑\n   </span>\n  </strong>\n  <span style='color: rgb(178, 178, 178);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n   <span leaf=\"\">\n    ：馨药\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      PR 稿对接\n     </span>\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb\n    </span>\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      投稿\n     </span>\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb；邮箱 insight@dxy.cn\n    </span>\n   </span>\n  </span>\n </p>\n <hr style='-webkit-tap-highlight-color: transparent;margin-bottom: 0em;outline: 0px;letter-spacing: 0.544px;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);border-style: solid;border-right-width: 0px;border-bottom-width: 0px;border-left-width: 0px;border-color: rgba(0, 0, 0, 0.1);transform-origin: 0px 0px;transform: scale(1, 0.5);visibility: visible;'/>\n <p style='-webkit-tap-highlight-color: transparent;margin: 8px 8px 0px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.75em;text-align: center;'>\n  <span leaf=\"\">\n   <img class=\"rich_pages wxw-img\" data-croporisrc=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgz1Wlk1fedI6iaPQXLtqOXQ3BB8BvMRTUWApMthfj466pTZVZOtAjUXw/0?wx_fmt=png&amp;from=appmsg\" data-cropselx2=\"562\" data-cropsely2=\"355\" data-imgfileid=\"100133280\" data-ratio=\"0.6829787234042554\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgz1Wlk1fedI6iaPQXLtqOXQ3BB8BvMRTUWApMthfj466pTZVZOtAjUXw/640?wx_fmt=png&amp;from=appmsg\" style=\"-webkit-tap-highlight-color: transparent;outline: 0px;color: rgb(51, 51, 51);letter-spacing: 1px;width: 100%;visibility: visible !important;height: auto !important;\"/>\n   <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\">\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\"/>\n   </img>\n  </span>\n </p>\n <p style=\"display: none;\">\n  <mp-style-type data-value=\"3\">\n  </mp-style-type>\n </p>\n</div>\n",
  "publish_time": 1750552701,
  "mp_id": "MP_WXS_3975077766",
  "pic_url": "https://mmbiz.qlogo.cn/mmbiz_jpg/lVFg8Ny0F8sfrH2Fh8k0NTibfMoWpicnGlibibCCLNVN9zZrMK8KBk0HXmiakyeXs3PDuRP0PfPicqaTRicE7GvxqLXHQ/0?wx_fmt=jpeg",
  "mp_name": "Insight数据库"
}